Elicio Therapeutics enters into merger agreement with Angion BiomedicaBusiness, R&D, TherapeuticsIn addition to becoming a Nasdaq-listed company, the focus of Elicio moving forward will be a therapeutic cancer vaccine candidate that targets mKRAS-driven tumors. Read more January 17, 2023/by BioSpace https://www.pharmalive.com/wp-content/uploads/2023/01/Nasdaq-Getty-Biospace.jpeg 350 625 BioSpace https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png BioSpace2023-01-17 10:23:332023-01-17 10:23:33Elicio Therapeutics enters into merger agreement with Angion Biomedica
